Our Experts Comment the Times Series

See All the Comments

Generically better

07 February 2020 by lberuti

Cardinal Health, Inc. (CAH) provides complementary products and services to healthcare providers and manufacturers. Their services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising. CAH CDS is a constituent of the CDX IG since s04. The 5y CDS is currently paying ~75bp. CAH CDS has reverted tighter by ~90bp from an OCT19 peak (~165) along with the broader sector as the opioid-linked risk faded. Yesterday CAH tightened -8 and its stock rose +12% on the back of better than expected performance in their pharmaceutical distribution segment. Indeed, the segment saw quarterly sales of $36b (+6%) profit of $462m (+4%) both beating consensus. During the call the company stated that for the first time in several quarters, their generics program reverted from being a net negative to being a net positive. Gross debt was ~ unchanged at $7.9b including $1.2b ST. Cash reported on balance sheet was $1.7b. Operating cash flow for the quarter was reported at ~$700m and FCF at ~$620m. CAH paid ~$140m in dividends and after the ~$350m share buybacks last quarter, they do not plan to buy more this year. In the call they reasserted their guidance to cut LT debt by >$1b in fy 2020. For reference the name is Baa2n / BBBs / BBBs and no imminent rating change is expected.